|
|
|
|
LEADER |
02215 am a22004693u 4500 |
001 |
100810 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Brennand, Kristen J.
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
100 |
1 |
0 |
|a Whitehead Institute for Biomedical Research
|e contributor
|
100 |
1 |
0 |
|a Jaenisch, Rudolf
|e contributor
|
700 |
1 |
0 |
|a Marchetto, M. Carol
|e author
|
700 |
1 |
0 |
|a Benvenisty, Nissim
|e author
|
700 |
1 |
0 |
|a Brustle, Oliver
|e author
|
700 |
1 |
0 |
|a Ebert, Allison
|e author
|
700 |
1 |
0 |
|a Izpisua Belmonte, Juan Carlos
|e author
|
700 |
1 |
0 |
|a Kaykas, Ajamete
|e author
|
700 |
1 |
0 |
|a Lancaster, Madeline A.
|e author
|
700 |
1 |
0 |
|a Livesey, Frederick J.
|e author
|
700 |
1 |
0 |
|a McConnell, Michael J.
|e author
|
700 |
1 |
0 |
|a McKay, Ronald D.
|e author
|
700 |
1 |
0 |
|a Morrow, Eric M.
|e author
|
700 |
1 |
0 |
|a Muotri, Alysson R.
|e author
|
700 |
1 |
0 |
|a Panchision, David M.
|e author
|
700 |
1 |
0 |
|a Rubin, Lee L.
|e author
|
700 |
1 |
0 |
|a Sawa, Akira
|e author
|
700 |
1 |
0 |
|a Soldner, Frank
|e author
|
700 |
1 |
0 |
|a Song, Hongjun
|e author
|
700 |
1 |
0 |
|a Studer, Lorenz
|e author
|
700 |
1 |
0 |
|a Temple, Sally
|e author
|
700 |
1 |
0 |
|a Vaccarino, Flora M.
|e author
|
700 |
1 |
0 |
|a Wu, Jun
|e author
|
700 |
1 |
0 |
|a Vanderhaeghen, Pierre
|e author
|
700 |
1 |
0 |
|a Gage, Fred H.
|e author
|
700 |
1 |
0 |
|a Jaenisch, Rudolf
|e author
|
245 |
0 |
0 |
|a Creating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders
|
260 |
|
|
|b Elsevier,
|c 2016-01-13T17:11:00Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/100810
|
520 |
|
|
|a As a group, we met to discuss the current challenges for creating meaningful patient-specific in vitro models to study brain disorders. Although the convergence of findings between laboratories and patient cohorts provided us confidence and optimism that hiPSC-based platforms will inform future drug discovery efforts, a number of critical technical challenges remain. This opinion piece outlines our collective views on the current state of hiPSC-based disease modeling and discusses what we see to be the critical objectives that must be addressed collectively as a field.
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Stem Cell Reports
|